Dapiglutide (formerly ZP 7570) is a dual GLP-1 and GLP-2 receptor agonist developed by Zealand Pharma.[1][2]
| Clinical data | |
|---|---|
| Other names | ZP 7570 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| Chemical and physical data | |
| Formula | C192H302N46O57 |
| Molar mass | 4166.793 g·mol−1 |
References
edit- ^ Reiner, Johannes; Berlin, Peggy; et al. (July 2022). "Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel". Journal of Parenteral and Enteral Nutrition. 46 (5): 1107–1118. doi:10.1002/jpen.2286. PMID 34705281.
- ^ Olsen, Minna B.; HöVelmann, Ulrike; et al. (1 June 2022). "335-OR: Dapiglutide, a Once-Weekly GLP-1R/GLP-2R Dual Agonist, Was Safe and Well Tolerated and Showed Dose-Dependent Body Weight Loss over Four Weeks in Healthy Subjects". Diabetes. 71 (Supplement_1). doi:10.2337/db22-335-OR. S2CID 249256542.
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |